SLC5A2 and heart failure: Over a median 2-year follow-up, SGLT2 inhibitors use was independently associated with a reduced risk of major adverse cardiovascular events (HR: 0.45), all-cause mortality (HR: 0.51), and heart failure hospitalization (HR: 0.40) [120].